Prostate-specific antigen doubling time in the identification of patients at risk for progression after treatment and biochemical recurrence for prostate cancer - 26/08/11
Abstract |
After primary treatment for clinically localized prostate cancer, biochemical recurrence is usually the first evidence of either local recurrence or metastatic progression. This poses a diagnostic dilemma for both the patient and the physician regarding future therapy. Prostate-specific antigen doubling time (PSADT) is a useful tool in this clinical setting. There have been multiple reports of the utility of PSADT in men with isolated biochemical recurrence after either radical prostatectomy or external-beam radiation therapy. Early observations of PSADT in men with recurrence are reviewed and the current literature is summarized to allow physicians to make an accurate assessment of a patient's risk of progression after isolated biochemical recurrence.
Le texte complet de cet article est disponible en PDF.Plan
Vol 62 - N° S
P. 2-8 - décembre 2003 Retour au numéro
Article précédent
- Introduction
- Kenneth J. Pienta
- Use of nomograms to predict the risk of disease recurrence after definitive local therapy for prostate cancer
- Christopher J Diblasio, Michael W Kattan
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?